|
Here’s the other thing that is confusing to
our physician colleagues, which is the so-called phases of chronic
hepatitis B. This was institutionalized by the NIH at a consensus
conference about 5 or 6 years ago in a publication in our
literature. They made the suggestion that we should try
to characterize our patients who have hepatitis B virus infection into
being either in the immunotolerant phase, the immunoactive phase that
in our lingo we call ‘chronic hepatitis B’, or who are inactive
carriers. Now how do we tell the difference? Well,
sometimes it takes more than one series of tests, but immunotolerant
phase are e-Positive, so they have the wild type, their DNA is high,
sometimes so high that it’s very frightening to the patient and to the
doctor, but the ALT is normal. So the concept here is that these are people
infected at birth or early in life, when their body’s immune system
was immature, and the virus was not seen as foreign. They were born with it, so the immune system
doesn’t see it as some sort of foreign protein in the body, so there’s
no immune reaction against the virus. For reasons that are unclear, some time in
early adult life, something triggers and the immune system begins to
see the virus as foreign, and that’s when the liver enzymes go up.
This is the immunoactive phase, when there’s
immune activity against the virus. From all of our studies with interferon,
lamivudine and adefovir, our drugs are most effective when given in
this phase because there’s two things going on: the body’s immune
system is trying to get rid of the virus, and then we prescribe an
anti-viral agent, so it’s sort of like a double hit, an active immune
system and an anti-viral agent. Therapy in the immunotolerant phase has not
been particularly effective in getting a sustained clearance of the
virus. And it’s OK, because although this is
frightening to doctors and patients sometimes, there’s really very
little going on in the liver. If you do liver biopsies, which we don’t routinely do, the
biopsies are normal or there’s just very minimal inflammation in the
liver. Now in the phase that we call chronic
hepatitis B, the e-antigen may be positive if it’s wild type, or
negative if it’s one of the two mutants, DNA is high, sometimes on
average a little less higher, the ALTs are elevated and patient may or
may not have symptoms. Most often there’s no symptoms, but there
may be some vague right upper quadrant aching that’s quite nonspecific
in nature. Now if all goes well, in the wild type, in
the immunoactive phase with the e-Positive, will go down to this phase
and will become an inactive HBsAg carrier. Now the old lingo we used to use was
“healthy carrier”, the NIH said that’s a misnomer, because these
people have infection, they’re still at risk for liver cancer, and to
use the word healthy is inaccurate. So the lingo now is inactive HBsAg carrier,
these are e-Negative, DNA becomes low now and is typically less than
10 to the fourth so you still may have detectable DNA, but the ALT
tends to be normal. These are the people that occasionally, in
the Chinese and Taiwanese study, may actually lose surface antigen and
have a clearance.
|